Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Glucotrack CBGM
product3 mentionslast seen Oct 22, 2026
An investigational long-term implantable continuous blood glucose monitoring system.
Relationships 6
- Glucotrack, Inc.developsGlucotrack CBGM99% confidence2 sources
- Glucotrack Technologies, Inc.developsGlucotrack CBGM99% confidence2 sources
- Glucotrack CBGMapplies todiabetes management90% confidence1 source
- Glucotrack CBGMapplies todiabetes90% confidence1 source
- Glucotrack, Inc.commercializesGlucotrack CBGM90% confidence1 source
- Glucotrack CBGMapplies todiabetes technology88% confidence1 source
Relationship
Glucotrack, Inc.developsGlucotrack CBGM
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 22, 2026Glucotrack, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 3.02: Unregistered Sales of Equity Securities; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system
- filingSEC EDGARSep 11, 2026Glucotrack, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 3.02: Unregistered Sales of Equity Securities; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
through its subsidiary Glucotrack Technologies, Inc., is also focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system